Michael A. Kass, M.D., of Washington University School of Medicine, St. Louis, and colleagues in the Ocular Hypertension Treatment Study Group compared the safety and efficacy of earlier vs. later ...

The FDA approved iDose TR for the treatment of open-angle glaucoma and ocular hypertension. Commercial launch activities for the implant are anticipated to begin in the first quarter of 2024.

The safety and efficacy of iDose TR was based on 2 randomized, parallel-group, double-masked, controlled phase 3 trials (ClinicalTrials.gov Identifier: GC-010 [NCT03519386], GC–012 [NCT03868124 ...

References Santen and UBE received FDA approval for Omlonti ® (omidenepag isopropyl ophthalmic solution) 0.002% for the reduction of elevated intraocular pressure in patients with primary open ...

The FDA approved Iyuzeh for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, according to a press release from Thea Pharma. Iyuzeh (latanoprost ophthalmic ...

The Ocular Hypertension Treatment Study (OHTS) is a multicentered, randomized, controlled clinical trial with the primary goal to determine the safety and efficacy of topical ocular hypotensive ...

Only about a quarter of patients with ocular hypertension lose peripheral vision, so clinicians should not recommend treatment to everyone with this condition, a long-term study suggests. The 20 ...

Under the terms of the agreement, Kowa receives exclusive rights to develop and commercialize NCX 470 in the US and all other ...

The ocular hypertension treatment market is highly competitive, with major players including Bausch + Lomb, Alcon, Santen Pharmaceutical, AbbVie, Nicox, Kowa, Qlaris Bio, Noveome Biotherapeutics ...

Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative thera ...